Entries by AP

2/2024

CH KILGER wins twice in EPO Board of Appeal Proceedings EPO revokes two more DNA-sequencing patents despite Illumina appeal. The EPO Boards of Appeal have confirmed the revocation of two more Illumina patents concerning DNA-sequencing technology. The same boards also issued a negative preliminary opinion concerning a third patent held by the US manufacturer of […]

11/2023

CH KILGER WAS IN ATTENDANCE OF THE CONFERENCE ON SUSTAINABLE AVIATION FUEL HELD FOR GOVERNMENT OFFICIALS IN DUBAI (UAE) IN NOVEMBER 2023. The International Civil Aviation Organization was the host of this politically important event for the entire aviation industry.

11/2023

INNOVATORS AND GOVERNMENTS MEET IN DUBAI FOR SUSTAINABLE AVIATION FUELS – ICAO 3 Well over a hundred countries and one thousand delegates are convening in Dubai this week to firm up their collective commitments to boost global aviation’s transition towards Sustainable Aviation Fuels (SAF), Lower Carbon Aviation Fuels (LCAF), and other cleaner energy sources.

1/2023

Webinar: STRAIN BANKING: HOW TO TRANSFORM SAMPLES INTO ASSETS 25 January 2023 / 90 Minutes Sponsored by Biomillenia

9/2022

UPC Publishes Rules of Procedure

3/2022

CH KILGER PREVAILS IN PATENT INFRINGEMENT PROCEEDINGS BEFORE THE HIGHER REGIONAL COURT OF MUNICH I

11/2020

CH KILGER ASSISTS DIDAC COSTA IN VENDÉE GLOBE RACE Innovation is needed for the world to solve the plastic problem 

12/2019

3 in ONE STRIKE  – ILLUMINA PATENTS INVALIDATED BY CH KILGER The European Patent Office has destroyed several patents belonging to Illumina, a US manufacturer of DNA sequencing machine and a market leader in the field.

07/2019

Engineering in Medicine an Biology (EMBC) Conference Invites Dr. Christian Kilger Dr. Colin Brenan, CEO 1CellBio and a famous serial entrepreneur from Boston, USA invited Patent Attorney Dr. Christian Kilger to talk at the EMBC conference in Berlin at the City Cube.

03/2019

Partial victory for AbbVie in biosimilar dispute Rheumatism drug Humira is one of pharmaceutical company AbbVie’s most valuable biosimilars. In ongoing disputes over the patent family, the European Patent Office Opposition Division finally rejected all oppositions in the oral hearing concerning the divisional application EP 2940 044. A significant aspect of the decision is the […]